Sci Pharmtech Stock Market Capitalization
| 4119 Stock | TWD 95.50 2.10 2.15% |
SCI Pharmtech fundamentals help investors to digest information that contributes to SCI Pharmtech's financial success or failures. It also enables traders to predict the movement of SCI Stock. The fundamental analysis module provides a way to measure SCI Pharmtech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SCI Pharmtech stock.
SCI |
SCI Pharmtech Company Market Capitalization Analysis
SCI Pharmtech's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current SCI Pharmtech Market Capitalization | 9.59 B |
Most of SCI Pharmtech's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SCI Pharmtech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of SCI Pharmtech is about 9.59 B. This is 25.93% lower than that of the Pharmaceuticals sector and 94.44% higher than that of the Health Care industry. The market capitalization for all Taiwan stocks is 49.63% higher than that of the company.
SCI Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SCI Pharmtech's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SCI Pharmtech could also be used in its relative valuation, which is a method of valuing SCI Pharmtech by comparing valuation metrics of similar companies.SCI Pharmtech is currently under evaluation in market capitalization category among its peers.
SCI Fundamentals
| Return On Equity | 0.0609 | |||
| Return On Asset | 0.0077 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 9.19 B | |||
| Shares Outstanding | 95.38 M | |||
| Shares Owned By Insiders | 48.80 % | |||
| Shares Owned By Institutions | 0.77 % | |||
| Price To Earning | 14.98 X | |||
| Price To Book | 2.62 X | |||
| Price To Sales | 11.33 X | |||
| Revenue | 864.22 M | |||
| Gross Profit | 208.09 M | |||
| EBITDA | 129.25 M | |||
| Net Income | 55.7 M | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 12.73 X | |||
| Total Debt | 3.65 M | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 3.24 X | |||
| Book Value Per Share | 37.30 X | |||
| Cash Flow From Operations | 280.28 M | |||
| Earnings Per Share | 2.13 X | |||
| Target Price | 86.0 | |||
| Number Of Employees | 14 | |||
| Beta | -0.0933 | |||
| Market Capitalization | 9.59 B | |||
| Total Asset | 4.19 B | |||
| Retained Earnings | 809 M | |||
| Working Capital | 1.02 B | |||
| Current Asset | 1.8 B | |||
| Current Liabilities | 782 M | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 4.21 % | |||
| Net Asset | 4.19 B |
About SCI Pharmtech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SCI Pharmtech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SCI Pharmtech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SCI Pharmtech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SCI Stock Analysis
When running SCI Pharmtech's price analysis, check to measure SCI Pharmtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SCI Pharmtech is operating at the current time. Most of SCI Pharmtech's value examination focuses on studying past and present price action to predict the probability of SCI Pharmtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SCI Pharmtech's price. Additionally, you may evaluate how the addition of SCI Pharmtech to your portfolios can decrease your overall portfolio volatility.